Testosterone in Women — The Basics

Women have testosterone levels roughly 10–15 times lower than men, but the hormone is biologically active at those levels. Testosterone declines gradually with age in women — more gradually than estrogen, and without the sharp drop that occurs at menopause. There is no clinically validated threshold that defines "low testosterone" in women the way the 300 ng/dL cutoff functions in men, which makes diagnosis more challenging and the use of testosterone levels to guide treatment less reliable.

This is an important starting point: unlike in men, testosterone testing in women is not recommended as a diagnostic tool for most complaints. The Global Consensus Position Statement — endorsed by 11 major international societies including the Endocrine Society and the North American Menopause Society — explicitly states that routine testosterone measurement has no proven clinical utility outside of monitoring during therapy.[6] A low number is not a diagnosis, and a normal number doesn't rule out a real problem.

The One Indication With Real Evidence: HSDD

Hypoactive sexual desire disorder (HSDD) — a persistent, distressing reduction in sexual desire that cannot be explained by another medical condition, medication, or relationship problem — is the only indication for testosterone therapy in women that is supported by consistent evidence from randomized controlled trials. The American College of Obstetricians and Gynecologists, the Endocrine Society, and the Global Consensus all agree on this point.[4][6][7]

📊 The Evidence — What Testosterone Does for HSDD

The Global Consensus reviewed the available trial data and found a moderate but meaningful treatment effect for testosterone in postmenopausal women with HSDD: approximately one additional satisfying sexual event per month compared to placebo.[6] That's a modest number in absolute terms — but for women who are distressed by low sexual desire, a consistent improvement in satisfying sexual experiences is clinically meaningful.

The evidence base is primarily in postmenopausal women. Evidence in premenopausal women is insufficient to support use, and neither ACOG nor the Global Consensus recommend testosterone for HSDD in premenopausal patients at this time.[4][6]

What Testosterone Does Not Have Evidence For in Women

This is where the evidence parts ways with the marketing. Testosterone is increasingly offered to women for a wide range of complaints — fatigue, weight gain, brain fog, mood, muscle tone, bone density. The Global Consensus reviewed the evidence for each of these indications specifically and reached the same conclusion across the board.

Evidence supports use for:

  • Hypoactive sexual desire disorder (HSDD) in postmenopausal women
  • Short-term use (up to 24 months) at physiologic doses

Evidence does not support use for:

  • General wellbeing or energy
  • Mood or depression
  • Cognitive performance or dementia prevention
  • Bone mineral density
  • Lean body mass, body fat, or muscle strength
  • Any symptom in premenopausal women
My Synthesis The pattern here is identical to what we see with testosterone in men and thyroid hormone broadly: a real, specific, evidence-supported indication gets stretched into a general wellness treatment for symptoms that trials don't show it actually improves. A woman coming in with fatigue, low mood, and reduced energy almost certainly does not have a testosterone problem — and even if her levels test low, the evidence says treating that number is unlikely to fix those symptoms. HSDD, with its specific definition and documented treatment response, is a real and valid indication. Fatigue is not.

Reference Ranges and Dosing in Women

One of the practical challenges with testosterone therapy in women is that there is no FDA-approved female formulation in the United States, and the lab ranges printed on standard reports are often based on immunoassay methods that are less accurate at the low levels found in women. The gold-standard measurement method is liquid chromatography-mass spectrometry (LC-MS/MS), and reference ranges based on that method tell a clearer story.

📊 The Evidence — Normal Testosterone Ranges in Women

In premenopausal women measured by LC-MS/MS, total testosterone typically falls between 9 and 46 ng/dL, with levels peaking around mid-cycle and declining in the luteal phase — though this variation is small relative to the wide range between individual women.[1][2] Testosterone declines with age even before menopause: women aged 35–39 have meaningfully lower levels than women aged 18–25, so age matters when interpreting a result.[1] After menopause, levels fall further but still overlap substantially with premenopausal ranges, which is one reason a low testosterone number alone is a poor guide to whether treatment is needed.[5]

There is no validated threshold below which symptoms reliably appear or above which treatment reliably helps — which is precisely why the Global Consensus recommends against using testosterone levels to diagnose HSDD or decide who to treat.[6]

Practical Dosing With Male Formulations

Since no female-specific product is approved in the US, the standard approach is to use a small fraction of a male transdermal gel formulation — typically about one-tenth of the standard male dose, targeting an absorbed dose of approximately 300 micrograms per day.[6][7] Male 1% gel formulations (10 mg/g) can be applied in small measured amounts to clean, dry skin on the thigh, abdomen, or upper arm, avoiding breast tissue.

⚠ My Recommendation on Target Levels When monitoring testosterone during therapy, I aim to keep total testosterone within the normal premenopausal physiologic range — and in practice I don't recommend exceeding 50–60 ng/dL. Levels above that range start to push into territory where androgen excess side effects become more likely, and the evidence for additional benefit above physiologic levels is nonexistent. The goal is restoration of normal physiology, not supraphysiologic dosing. If a patient's levels are consistently above 60 ng/dL on a given dose, that dose is too high regardless of how they feel.

Formulations: What's Recommended and What Isn't

The route of delivery matters significantly — both for safety and for the ability to adjust or stop treatment if problems arise.

Route Recommendation Key Considerations
Transdermal gel or cream Preferred Dose can be adjusted or stopped easily. Mild acne and hair growth are the main side effects at appropriate doses. No short-term lipid effects at physiologic doses.
Compounded preparations Use with caution Uncertain absorption and dosing consistency. Acceptable if no other option exists, but requires careful monitoring. Supraphysiologic doses are a common problem.
Oral testosterone Not recommended Adverse effects on cholesterol — reduces HDL (the "good" cholesterol) and raises LDL and triglycerides. Systemic oral androgens should be avoided.
Pellets Not recommended Cannot be removed or adjusted once implanted. Associated with supraphysiologic testosterone levels, irreversible virilization (voice changes, clitoral enlargement), abnormal uterine bleeding, mood swings, and acne. Studies document these harms specifically.
Injections Not recommended Produces supraphysiologic levels with significant fluctuation. Difficult to titrate to the low doses appropriate for women.

Side Effects and What's Irreversible

At physiologic doses via transdermal route, the most common side effects are mild acne and increased facial or body hair growth (hirsutism). These are usually manageable. At higher doses — which is where compounded preparations and pellets most often land — side effects become more significant and some are not reversible.

⚠ Irreversible and Serious Side Effects at Higher Doses
  • Voice deepening: Once the voice changes, it does not return to baseline after stopping testosterone.
  • Clitoral enlargement: Partially or fully irreversible depending on degree.
  • Scalp hair loss: In women with genetic predisposition, testosterone can accelerate hair thinning that may not fully reverse.
  • Virilization (masculine facial features, jawline changes): Not reversible with short courses at high doses.
These effects are more likely with pellets, injections, and compounded preparations at supraphysiologic doses — the same formulations that are most aggressively marketed in wellness settings.[4][5]

The Unknowns: Breast Cancer and Cardiovascular Risk

Two important safety questions remain genuinely unanswered, and honest communication with patients requires naming them directly.

Breast cancer: The effect of testosterone on breast cancer risk in women is unknown. Most existing data involve estrogen-plus-testosterone combinations rather than testosterone alone, which makes it impossible to isolate testosterone's contribution. Some observational data are reassuring; no randomized trial has been powered to detect a breast cancer signal. Women with a personal or strong family history of hormone-sensitive breast cancer should discuss this uncertainty explicitly before starting testosterone.[4][5]

Cardiovascular risk: Transdermal testosterone at physiologic doses has not been associated with increases in blood pressure, blood glucose, or HbA1c in short-term trials. A trend toward increased DVT risk has been observed, though concurrent estrogen therapy in many study participants complicates the interpretation. Long-term cardiovascular data are lacking, and women at high cardiometabolic risk were generally excluded from trials.[6]

📊 The Evidence — Duration Limits Safety and efficacy data for testosterone in women extend to a maximum of 24 months in clinical trials.[7] Beyond that window, the evidence simply doesn't exist. The Global Consensus recommends a 6-month trial to assess clinical benefit — if no improvement is seen by 6 months, the therapy should be discontinued.[6] This is a meaningful difference from the way testosterone is often presented in wellness settings, where it is marketed as an indefinite maintenance therapy.

Monitoring During Treatment

When testosterone is appropriately prescribed for HSDD in postmenopausal women, the monitoring approach recommended by the Endocrine Society and Global Consensus is straightforward:

⚠ Recommended Monitoring Protocol
  • Before starting: Measure baseline testosterone to exclude already-elevated levels — not to diagnose HSDD
  • 3–6 weeks after starting: Recheck testosterone to confirm levels are in physiologic range
  • Every 6 months: Monitor testosterone levels and check for signs of androgen excess — acne, hirsutism, voice changes
  • At 6 months: Assess clinical benefit — if no improvement, discontinue
  • Maximum studied duration: 24 months; ongoing use beyond this is outside the evidence base
My Synthesis Testosterone for women is one of the areas where I'm most direct about the gap between what the evidence supports and what patients are sometimes being offered. The HSDD indication is real — one additional satisfying sexual event per month is a meaningful outcome for a woman who is genuinely distressed by low desire, and transdermal therapy at physiologic doses is reasonably safe for up to two years. What I won't do is prescribe pellets or compounded high-dose preparations for fatigue, energy, or general wellbeing — the evidence isn't there, the side effects at those doses are real and some are permanent, and the inability to remove a pellet if something goes wrong is a clinical problem I'm not willing to create for a patient. The breast cancer and long-term cardiovascular unknowns are also part of every conversation I have before starting treatment.